Just caught this - HOOKIPA is offloading their cancer immunotherapy programs to NeoTrail Therapeutics. They're selling off HB-200 and HB-700, which is interesting timing. HB-200 was their HPV cancer candidate that showed some decent Phase 2 data last year with pembrolizumab, got the FDA Fast Track nod too. HB-700 is the KRAS mutation play for lung and colorectal cancers, already cleared for clinical trials. Deal closed sometime around now supposedly, Q2 2026 timeframe. The financial terms are locked down but they're not saying numbers, which is typical for these asset deals. Makes sense they're passing it off to a private firm like NeoTrail though - probably needed the cash runway more than they needed to push these through late stage trials. HOOKIPA still has HB-300 for prostate cancer and their Hep B and HIV programs in the pipeline, so not completely pivoting away from immuno-oncology. Stock was hovering around $1.04 last I checked. Curious to see if NeoTrail can actually move the needle on these candidates or if they just sit on them.